0000000000040470

AUTHOR

Heinz-j. Schmitt

showing 13 related works from this author

New methods of delivery of amphotericin B.

1993

Fungal infections continue to be a major problem in the management of immunocompromised patients. Despite its formidable toxicity and treatment failures, amphotericin B is still the drug of choice for most of these infections. One strategy for reducing the toxicity of amphotericin B and thus permitting administration of higher doses is that of using less toxic formulations. Entrapping amphotericin B into liposomes or binding it to other substances reduces its toxicity to host cells, whereas the selective binding of amphotericin B to ergosterol preserves its toxicity to fungal cells. Adding fungus-specific antibodies to such liposomes may further increase the efficiency of drug targeting. Th…

Microbiology (medical)DrugTime Factorsmedia_common.quotation_subjectPharmacologyAspergillosisRoute of administrationImmunocompromised HostAmphotericin BAmphotericin BMedicineAnimalsAspergillosisHumansAdministration Intranasalmedia_commonAerosolsDosage Formsbusiness.industrymedicine.diseaseClinical trialInfectious DiseasesTargeted drug deliveryMycosesToxicityNasal administrationbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Efficacy of Acellular Pertussis Vaccine in Early Childhood After Household Exposure

1996

Objective. —To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against "typical" pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design. —Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting. —Six areas in Germany with a high incidence of pertussis. Subjects. —Four hundr…

Bordetella pertussismedicine.medical_specialtyPediatricsbiologybusiness.industryIncidence (epidemiology)General MedicineEnvironmental exposurebiology.organism_classificationmedicine.diseaseVaccine efficacyVaccinationImmunizationEpidemiologyImmunologyMedicinebusinessWhooping coughJAMA: The Journal of the American Medical Association
researchProduct

Pneumococcal conjugate vaccines in Europe, Berlin, Germany, 23–25 August 2000. Report of a European Advisory Board meeting

2001

Pediatricsmedicine.medical_specialtyInfectious DiseasesGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthmedicineMolecular MedicineLibrary sciencebusinessConjugateVaccine
researchProduct

Immunogenicity and reactogenicity of a bicomponent and a tricomponent acellular pertussis-diphtheria-tetanus (DTaP) vaccine in primary immunization a…

1996

Abstract Objectives: To compare the immunogenicities and reactogenicities of bicomponent (B) (pertussis toxoid, filamentous hemagglutinin) and tricomponent (T) (pertussis toxoid, filamentous hemagglutinin, pertactin) acellular pertussis vaccines when coadministered with diphtheria and tetanus toxoids in primary (3, 4, and 5 mo) and booster (15–19 mo) vaccinations. Design and Methods: A randomized, double-blind study involving 175 children aged 12 to 18 weeks. Reactogenicity was based on diary cards, immunogenicity assessed by ELISA measurements of serum IgG antibodies. Results: There were no clinically relevant differences in local (B = 34.5; T=31.3%) and general (B = 43.9; T=41.8%) reactog…

Microbiology (medical)ReactogenicityTetanusbusiness.industrypertussisDiphtheriaToxoidFilamentous haemagglutinin adhesinGeneral MedicineBooster dosetoxoidmedicine.diseasecomplex mixturesVirologypertactinVaccinationacellular hemagglutininInfectious DiseasesImmunologymedicinePertactinbusinessInternational Journal of Infectious Diseases
researchProduct

Symptoms and complications of pertussis in adults

1995

There is increasing evidence that pertussis occurs frequently in adults, but there is limited information on the clinical course of this disease beyond childhood. A household contact study on the efficacy of an acellular pertussis vaccine was used to study the symptoms of pertussis in adults. Among 257 patients with pertussis identified in 121 families during a two-year period in one study center with a low whole-cell pertussis-vaccine uptake, 79 (30.7%) were adults, aged 19–83 years (mean age: 36 years) with a 1:1.8 male to female ratio. Ninety-one percent of the adults suffered from coughing (mean duration: 54 days), and in 80% this cough lasted ≥ 21 days. Whoops were rare (8%), whereas c…

AdultMaleSleep Wake DisordersMicrobiology (medical)Pediatricsmedicine.medical_specialtyVomitingWhooping CoughPainPoison controlEnzyme-Linked Immunosorbent AssaySweatingSneezingBordetella pertussisNasopharynxmedicineHumansProspective StudiesChildProspective cohort studyWhooping coughAgedAged 80 and overPertussis VaccineHoarsenessbusiness.industryHeadacheGeneral MedicineMiddle Agedmedicine.diseaseAntibodies BacterialAirway ObstructionInfectious DiseasesCoughAnesthesiaVomitingPertussis vaccineFemaleHeadachesmedicine.symptomChokingComplicationbusinessmedicine.drugInfection
researchProduct

B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination

2006

MalePediatricsmedicine.medical_specialtyddc:618General VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccination/adverse effectsddc:616.07Diphtheria-Tetanus-acellular Pertussis Vaccines/adverse effectsVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesSudden Infant Death/blood/epidemiologyVaccines Combined/adverse effectsmedicineHumansMolecular MedicineFemaleHepatitis B VaccinesbusinessDiphtheria-Tetanus-Pertussis VaccineSudden infant deathVaccine
researchProduct

O início de uma nova era: teste sistemático para patógenos causadores de infecções agudas das vias aéreas superiores (IVAS) em crianças

2007

On average humans get sick ten times per year. About six times the illness is due to an acute respiratory tract infection (ARI). Morbidity is especially high in children since they usually encounter the offending organism for the first time in their life; the lack of immunity results in shedding of the offending organisms in high numbers of prolonged time as compared to adults; their airways are smaller than those of adults and thus the inflammatory response leads to a more significant narrowing of the airways resulting in more severe disease; on average they have a high number of social contacts and also a more intimate contact with peers and caregivers alike resulting in a higher attack r…

education.field_of_studyPediatricsmedicine.medical_specialtyRespiratory tract infectionsbusiness.industrymedia_common.quotation_subjectPopulationAttack rateSevere diseaseSystematic testingImmunityHygienePediatrics Perinatology and Child HealthMedicineeducationbusinessAcute respiratory tract infectionmedia_commonJornal de Pediatria
researchProduct

Age-Dependent Association of Human Mannose-Binding Lectin Mutations With Susceptibility to Invasive Meningococcal Disease in Childhood

2007

Mannose-binding lectin (MBL) is an important factor of the innate immune system, and MBL-initiated complement activation is an important early defense mechanism against various bacterial infections, including invasive meningococcal disease.In a pediatric cohort (ages 2-215 months) with invasive meningococcal disease, we investigated the overall and age-stratified frequency of 3 MBL exon 1 variations (C154T, G161A, G170A), previously shown to result in markedly decreased MBL plasma concentrations, by allele specific fluorescent hybridization probe real-time PCR assays and direct sequencing. Healthy age-matched volunteers with the same ethnic background and no history of meningococcal disease…

MaleMicrobiology (medical)AgingAdolescentMannosechemical and pharmacologic phenomenaMeningococcal diseasemedicine.disease_causeMannose-Binding Lectinchemistry.chemical_compoundPrevalencemedicineHumansGenetic Predisposition to DiseaseChildMannan-binding lectinMutationInnate immune systembiologybusiness.industryInfantLectinbacterial infections and mycosesmedicine.diseaseComplement systemMeningococcal InfectionsInfectious DiseaseschemistryChild PreschoolMutationPediatrics Perinatology and Child HealthImmunologyCohortbiology.proteinFemalebusinessPediatric Infectious Disease Journal
researchProduct

CSF shunt infections in children

1993

The incidence of shunt infections and possible risk factors was investigated by chart analysis. From 1986 to 1989 350 shunt procedures were performed including 273 ventriculoperitoneal shunts and 75 ventriculoatrial shunts. Twenty-eight infectious episodes (8%) occurred in 25 patients during a median follow-up time of 20 months. For 204 patients the follow-up time could be prolonged until September 1992. In these patients no infectious episodes occurred in the extended observation period. In 24 cases (85.7%) a causative organism could be isolated. The infecting organisms were gram-positive cocci in 22 cases (78.6%) and gram-negative bacilli in two cases. The main signs and symptoms were fev…

MaleReoperationMicrobiology (medical)medicine.medical_specialtyAbdominal painAdolescentmedicine.drug_classAntibioticsVentriculoperitoneal ShuntRecurrenceRisk FactorsmedicineHumansHeart AtriaDerivationChildGram-Positive Bacterial InfectionsAntibacterial agentbusiness.industryInfant NewbornInfantGeneral Medicinemedicine.diseaseCerebrospinal Fluid ShuntsAnti-Bacterial AgentsSurgeryHydrocephalusInfectious DiseasesChild PreschoolEtiologyFemalemedicine.symptomGram-Negative Bacterial InfectionsComplicationbusinessShunt (electrical)Follow-Up StudiesHydrocephalusInfection
researchProduct

Conjugated vaccines: A new strategy for prevention and protection against pediatric infectious diseases

2002

Pharmacologybusiness.industryPediatric Infectious DiseaseConjugated vaccinesbook.journalMedicinePharmacology (medical)businessbookVirologyCurrent Therapeutic Research
researchProduct

Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C co…

2007

ABSTRACT We evaluated two formulations of a new combined Haemophilus influenzae type b (Hib)-meningococcal serogroup C (MenC)-tetanus toxoid (TT) conjugated vaccine and two formulations of a new MenC-TT vaccine (trials 711202/001 and 711202/008; clinical trial register numbers NCT00135486 and NCT00135564 [ www.ClinicalTrials.gov ]). A total of 520 healthy infants were randomized to receive primary vaccination (at 2, 3, and 4 months) with either MenC-TT plus diphtheria-tetanus-acellular pertussis (DTPa)-hepatitis B virus (HBV)-inactivated poliovirus (IPV)/Hib, Hib-MenC-TT plus DTPa-HBV-IPV, or MenC-CRM 197 plus DTPa-HBV-IPV/Hib (control). At 12 to 15 months, subjects received a polysaccharid…

Microbiology (medical)Clinical BiochemistryImmunologyPopulationMeningococcal VaccinesMeningococcal vaccineNeisseria meningitidis Serogroup CMeningococcal diseasemedicine.disease_causecomplex mixturesHaemophilus influenzaeAntigen-Antibody ReactionsConjugate vaccineImmunology and AllergyMedicineHumanseducationHaemophilus Vaccineseducation.field_of_studyAntigens BacterialReactogenicityVaccines Conjugatebusiness.industryNeisseria meningitidisInfantmedicine.diseaseVaccine ResearchVirologyAntibodies BacterialHaemophilus influenzaeVaccinationImmunologybusinessImmunologic MemoryClinical and vaccine immunology : CVI
researchProduct

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infant…

2007

The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC …

MaleImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineMeningitis Meningococcalmedicine.disease_causeMeningococcal diseaseConjugate vaccinemedicineHumansHepatitis B VaccinesVaccines CombinedHepatitis B AntibodiesBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHepatitis B virusReactogenicityMicrobial ViabilityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunologyMolecular MedicineFemalebusinessImmunologic MemoryVaccine
researchProduct

Factors influencing vaccine uptake in Germany.

2001

While vaccines have virtually eliminated many infectious diseases in Germany, vaccination coverage in children, adolescents and adults is still unsatisfying. This situation is mainly due to inadequate remuneration of vaccination services, structural deficits in the health care system and a lack of motivation. Political support and leadership would most likely be able to change this situation.

medicine.medical_specialtyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic healthVaccinationPublic Health Environmental and Occupational HealthVaccinationPoliticsInfectious DiseasesVaccination coverageEnvironmental healthGermanyEpidemiologyHealth careImmunologymedicineRemunerationMolecular MedicineHumansbusinessVaccine
researchProduct